Article

Driver of NSCLC Also Present in 23% of Small Cell Lung Cancer

Results presented at the American Association for Cancer Research Annual Meeting 2015 show the presence of a known driver of non-small cell lung cancer in small cell lung cancer, implying that promising treatments for the former may be applicable to the latter form of the disease.

Significant new treatments are available or in clinical trials for non-small cell lung cancer (NSCLC). The same explosion in treatment options is not true for the disease’s cousin, small cell lung cancer, the less common and more aggressive form of the disease. Results presented by the University of Colorado Cancer Center at the American Association for Cancer Research Annual Meeting 2015 show the presence of a known driver of NSCLC in small cell lung cancer, implying that promising treatments in development for the first may be applicable to the second form of the disease as well.

“There is an unmet need in small cell lung cancer. There have been no significant new therapies developed in 20 years,” says Fred R. Hirsch, MD, PhD, associate director for international programs at the University of Colorado Cancer Center and CEO of the International Association for the Study of Lung Cancer.

Read more at the Colorado Cancer Blogs: http://bit.ly/1cWEdEm

Related Videos
1 KOL is featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Parth Rali, MD
1 KOL is featured in this series.
4 KOLs are featured in this series
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo